Trial · NCT02208154
Ecological Effects of Decolonisation Strategies in Intensive Care
NCT02208154, Phase 3, Completed, MJM Bonten
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Ecological Effects of Decolonisation Strategies in Intensive Care. Trials, record NCT02208154. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02208154
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ecological Effects of Decolonisation Strategies in Intensive Care
- NCT number
- NCT02208154
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 8,665 participants, actual
- Lead sponsor
- MJM Bonten
- Conditions
- ICU-ecology (Multidrug Resistant Bacteria), ICU-acquired Bacteraemia
- Interventions
- Chlorhexidine oral care (CHX-Oro), Selective oropharyngeal decontamination (SOD), Selective Digestive Decontamination (SDD)
- First posted
- 2014-08-04
- Last updated
- 2017-11-01
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | ICU-Ecology | 27 months | To determine the ecological effects of decolonisation regimens (SDD, SOD and CHX-Oro) in reducing (MDR-GNB) ICU-acquired bacteraemia when compared to standard care. |
| Secondary | Cross-transmission rates | 27 months | To quantify cross-transmission rates with MDR-GNB during 3 decolonisation regimens and during standard care. |
| Secondary | Respiratory tract colonization | 27 months | To determine the effectiveness of 3 decolonisation regimens (SDD, SOD and CHX-Oro) in reducing acquired respiratory tract colonisation with MDR-GNB when compared to standard care. |
| Secondary | ward-level systemic antibiotic use | 27 months | To quantify the effects of 3 decolonisation regimens (SDD, SOD and CHX-Oro) in ICU patients on overall systemic antibiotic use when compared to standard care. |
| Secondary | colonization in relation to bacteraemia | 27 months | To quantify on ICU level the associations between intestinal and respiratory tract colonisation with GNB and the occurrence of ICU-acquired GNB bacteraemia. |
| Secondary | transmission capacities of different bacteria | 27 months | To quantify species-specific nosocomial transmission capacities (reproductive number per hospital admission, RA) of MDR-GNB during 3 decolonisation regimens and during standard care. |
| Secondary | Patient survival | 27 months | To determine the effectiveness of 3 decolonisation regimens (SDD, SOD and CHX-Oro) in reducing day-28 and in hospital mortality when compared to standard care. |
| Secondary | bacteraemia with resistant bacteria | 27 months | To determine ICU-acquired bacteraemia rates caused by any multi-drug resistant micro-organism, including MRSA, VRE, MDR-GNB, Acinetobacter, S. maltophilia, and ceftazidime- and/or carbapenem resistant P. aeruginosa, during each phase of the study. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02208154
GET https://conductscience.org/api/trials/v1/NCT02208154/registered